198 related articles for article (PubMed ID: 7886126)
1. [Comparison of the bioavailabilities of erythromycin estolate and erythromycin ethylsuccinate dry suspension preparations in steady state].
Potthast H; Schug B; Elze M; Schwerdtle R; Blume H
Pharmazie; 1995 Jan; 50(1):56-60. PubMed ID: 7886126
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of erythromycin after the administration of intravenous and various oral dosage forms to dogs.
Albarellos GA; Kreil VE; Ambros LA; Waxman S; Montoya L; Tarragona L; Quaine PC; Hallu RE; Rebuelto M
J Vet Pharmacol Ther; 2008 Dec; 31(6):496-500. PubMed ID: 19000270
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.
Croteau D; Bergeron MG; LeBel M
Antimicrob Agents Chemother; 1988 Apr; 32(4):561-5. PubMed ID: 3259856
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age.
Patamasucon P; Kaojarern S; Kusmiesz H; Nelson JD
Antimicrob Agents Chemother; 1981 May; 19(5):736-9. PubMed ID: 6975059
[TBL] [Abstract][Full Text] [Related]
5. Plasma bactericidal activity after administration of erythromycin estolate and erythromycin ethylsuccinate to healthy volunteers.
Bérubé D; Kirouac D; Croteau D; Bergeron MG; Lebel M
Antimicrob Agents Chemother; 1988 Aug; 32(8):1227-30. PubMed ID: 3142349
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of erythromycin ethylsuccinate after intragastric administration to healthy foals.
Lakritz J; Wilson WD; Marsh AE; Mihalyi JE
Vet Ther; 2002; 3(2):189-95. PubMed ID: 19750750
[TBL] [Abstract][Full Text] [Related]
7. Management of group A streptococcal pharyngitis: a randomized controlled study of twice-daily erythromycin ethylsuccinate versus erythromycin estolate.
Ginsburg CM; McCracken GH; Steinberg JB; Crow SD; Dildy BF; Lancaster K; Olsen K
Pediatr Infect Dis; 1982; 1(6):384-7. PubMed ID: 6761656
[No Abstract] [Full Text] [Related]
8. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
Keeffe EB; Reis TC; Berland JE
Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110
[TBL] [Abstract][Full Text] [Related]
9. Erythromycin therapy for group A streptococcal pharyngitis. Results of a comparative study of the estolate and ethylsuccinate formulations.
Ginsburg CM; McCracken GH; Crow SD; Dildy BR; Morchower G; Steinberg JB; Lancaster K
Am J Dis Child; 1984 Jun; 138(6):536-9. PubMed ID: 6372437
[TBL] [Abstract][Full Text] [Related]
10. Selection of an oral erythromycin product.
Fraser DG
Am J Hosp Pharm; 1980 Sep; 37(9):1199-205. PubMed ID: 6998290
[TBL] [Abstract][Full Text] [Related]
11. Absorption of erythromycin. A cross-over study in healthy volunteers.
Männistö P; Tuomisto J; Räsänen R
Arzneimittelforschung; 1975 Nov; 25(11):1828-31. PubMed ID: 1106445
[TBL] [Abstract][Full Text] [Related]
12. Bioinequivalence of erythromycin ethylsuccinate and enteric-coated erythromycin pellets following multiple oral doses.
Yakatan GJ; Rasmussen CE; Feis PJ; Wallen S
J Clin Pharmacol; 1985; 25(1):36-42. PubMed ID: 3871797
[TBL] [Abstract][Full Text] [Related]
13. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group.
Hoppe JE
Pediatr Infect Dis J; 1992 Mar; 11(3):189-93. PubMed ID: 1565532
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.
Welling PG; Elliott RL; Pitterle ME; Corrick-West HP; Lyons LL
J Pharm Sci; 1979 Feb; 68(2):150-5. PubMed ID: 423080
[TBL] [Abstract][Full Text] [Related]
15. Concentrations of erythromycin in serum and tonsil: comparison of the estolate and ethyl succinate suspensions.
Ginsburg CM; McCracken GH; Culbertson MC
J Pediatr; 1976 Dec; 89(6):1011-3. PubMed ID: 792404
[TBL] [Abstract][Full Text] [Related]
16. Influence of alcohol consumption on erythromycin ethylsuccinate kinetics.
Morasso MI; Chávez J; Gai MN; Arancibia A
Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):426-9. PubMed ID: 2258252
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the gastrointestinal side effects of two forms of erythromycin.
Anastasio GD; Robinson MD; Little JM; Leitch BB; Pettice YL; Norton HJ
J Fam Pract; 1992 Nov; 35(5):517-23. PubMed ID: 1431767
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of erythromycin ethylsuccinate and its metabolite erythromycin in human plasma using liquid chromatography-electrospray ionization mass spectrometry for clinical study.
Gu Y; Wang G; Sun J
J Pharm Biomed Anal; 2006 Feb; 40(3):737-43. PubMed ID: 16376051
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability and stability of erythromycin delayed release tablets.
Ogwal S; Xide TU
Afr Health Sci; 2001 Dec; 1(2):90-6. PubMed ID: 12789122
[TBL] [Abstract][Full Text] [Related]
20. Comparative bioavailability evaluation of erythromycin base and its salts and esters. I. Erythromycin estolate capsules versus enteric-coated erythromycin base tablets.
DiSanto AR; Tserng KY; Chodos DJ; DeSante KA; Albert KS; Wagner JG
J Clin Pharmacol; 1980 Jul; 20(7):437-43. PubMed ID: 7430412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
